1. Impacting CV Risk With Diabetes Medications

3. Introduction/Overview

4. CVOTs in T2DM

5. CVOT GLP-1 RA Summary Results: ELIXA, LEADER, SUSTAIN-6

6. December 2008 FDA Guidance on Evaluating CV Risk in New Antidiabetic Therapies for T2DM

7. DEVOTE: Composite Primary Outcome Results

8. DEVOTE: Secondary Outcomes -- Hypoglycemia

9. Hypoglycemia and CV Risk in Patients With T2DM

10. Primary MACE Outcome CANVAS

11. CANVAS: CV Results

12. CANVAS: Renal Outcomes

13. CANVAS: 2-Fold Increase in Risk of Amputation, Canagliflozin vs Placebo

14. CANVAS Results: Benefits and Risks

15. EMPA-REG OUTCOME: Trial Design

16. EMPA-REG Primary Outcome (3-Point MACE): CV Death, Nonfatal MI, or Nonfatal Stroke

17. EMPA-REG Outcome: Results for CV Death

18. EMPA-REG Outcome and CANVAS: Hospitalization for HF

19. EMPA-REG Outcome: AEs

20. Mechanisms of Action and Amputations: Empagliflozin vs Canagliflozin

21. SGLT2 Inhibitors and Reduced Volume Overload

22. The "Fuel Hypothesis" as Explanation of Empagliflozin's Cardiorenal Benefits

23. Other Potential Mechanisms for CV Benefit Associated With Empagliflozin

24. Practice Patterns Changing Based on CVOT Data

25. LEADER: Time to First Renal Event

26. Intensive Glycemic Control Increased All-Cause Mortality (ACCORD)

27. Summary and Conclusions

28. Abbreviations

29. Abbreviations